High Dose Ascorbic Acid to Treat CMT1A

- MDA & CMTA are sponsors
- Futility Design
- WSU, Hopkins, U Rochester are sites
- CMTNS is primary outcome measure
- Skin biopsy as a secondary measure
CMT1A Trial

- 90 patients enrolled
- Goal is 100 patients in trial
- 8 drop outs
- Goal is to close enrollment by years end

- Starting to see patients for 18 month visit
- GI side effects have not proved limiting